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Abstract
Background: Angiogenesis, crucial for tumor progression, is a process regulated in the tissue
micro-environment. Vascular endothelial growth factor (VEGF) is a potent stimulatory factor of
angiogenesis and a negative prognostic indicator of breast cancer. VEGF is biologically active in the
extracellular space and hitherto, there has been a lack of techniques enabling sampling of angiogenic
molecules such as VEGF in situ. The majority of breast cancers are estrogen-dependent, and
estrogen has been shown to regulate VEGF in normal breast tissue and experimental breast cancer.
We investigated if microdialysis may be applicable in human breast cancer for sampling of
extracellular VEGF in situ and to explore if there is an association with local estradiol and VEGF
levels in normal and cancerous breast tissue.
Methods: Microdialysis was used to sample VEGF and estradiol in tumors and adjacent normal
breast tissue in postmenopausal breast cancer patients. VEGF and estradiol were also measured in
plasma, and immunohistochemical staining for VEGF was performed on tumor sections.
Results: We show that in vivo levels of extracellular VEGF were significantly higher in breast cancer
tumors than in normal adjacent breast tissue. There was a significant positive correlation between
estradiol and extracellular VEGF in normal breast tissue. However, no correlation was detected
between estradiol and VEGF in tumors or between tumor VEGF and plasma VEGF.
Conclusion: We conclude that VEGF and estradiol correlates significantly in normal breast tissue.
Microdialysis may be used to provide novel insight in breast tumor biology and the regulation of
molecules in the extracellular space of human breast tumors in vivo.
Background
Vascular endothelial growth factor (VEGF) is a potent
mediator of tumor angiogenesis, including neovasculari-
zation in human breast cancer [1]. In breast cancer
patients, high tumor VEGF levels, as assessed by immuno-
histochemistry or quantitative immunoassay, appear to
correlate with poor prognosis and decreased overall sur-
vival for both node-positive and node-negative breast can-
cer patients [2-4]. VEGF exists in several isoforms; the
shorter isoforms are diffusible proteins whereas the longer
isoforms are sequestered in the extracellular matrix [5].
Proteolytic cleavage may convert the longer VEGF iso-
forms into soluble, bioactive forms in the extracellular
space where they become available to endothelial cells
[5]. Sex steroids have been shown to increase VEGF
expression in normal breast tissue as well as in experimen-
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tal breast cancer, both in vitro and in vivo [6-10], and an
estrogen responsive element (ERE) has been identified in
the promoter region of the gene for VEGF [11].
Estrogen exposure is considered a major risk factor for
development of breast cancer and the majority of breast
cancers maintain their hormonal dependency [12,13].
After menopause the circulating levels of estradiol are
greatly reduced, yet postmenopausal women have been
shown to maintain breast tissue estradiol levels higher
than corresponding plasma levels [14]. Moreover, levels
of estradiol in breast tumor tissue have been shown to be
higher than those in normal breast tissue distant from the
tumor [14,15], and the major enzymes involved in estro-
gen synthesis – aromatase, sulphatase, and 17β-hydroxys-
teroid dehydrogenase – have been demonstrated in
human breast cancer [16-18]. As VEGF may be released
and estradiol metabolized locally in the breast, an in situ
technique for surveying these molecules may provide
novel insight into their regulation in tumor tissue in vivo.
We have previously used microdialysis for in vivo meas-
urements of estradiol, VEGF, and other molecules in nor-
mal human breast and experimental breast cancer [6-
8,19-21]. In this study we have performed microdialysis
in breast cancer patients in order to sample estradiol and
VEGF locally in breast cancer tumors and in adjacent nor-
mal breast tissue. We found that extracellular levels of
VEGF were significantly higher in tumors than in normal
breast tissue in vivo. In addition, we show a positive corre-
lation between normal breast tissue and plasma levels of
estradiol and extracellular VEGF in normal breast tissue in
vivo.
Methods
Subjects
Ten postmenopausal women, ages 51–86, participated in
the study. Postmenopausal status was defined by having
no spontaneous menstrual bleeding for at least a year in
women older than 50. None of the women had ongoing
hormonal treatment. The study was approved by the local
ethical review board in Linköping, Sweden, (reference
number 03–081) and performed in compliance with the
Helsinki Declaration, and all women gave informed con-
sent. Patient characteristics are provided in Table 1.
Microdialysis
Microdialysis was performed on the day before or the
same day as surgery using microdialysis catheters with a
molecular weight cut-off of 100,000 Da (CMA Microdial-
ysis AB, Stockholm, Sweden). Each catheter consists of a
tubular dialysis membrane (length 10 mm; diameter 0.52
mm) attached to a double-lumen tube (length 100 mm;
diameter 0.8 mm). Prior to microdialysis, mepivacaine
(0.3 mL; 5 mg/mL) was administered intracutaneously as
a local anesthetic. Two microdialysis catheters were there-
after inserted in the affected breast, one intratumorally
and one in adjacent, macroscopically normal breast tis-
sue. The insertion was guided by catheters for intravenous
use (Venflon, 1.4 mm; BOC Ohmeda AB, Helsingborg,
Sweden). The microdialysis catheters were connected to a
microinfusion pump (CMA 107, CMA Microdialysis AB)
and perfused with NaCl (154 mM) and dextran-70 (40 g/
L) at a rate of 0.5 μL/min. After an equilibration period of
30 minutes, the outgoing dialysate was collected and
stored together with plasma samples at -70°C for subse-
quent analysis. No complications occurred during or after
the microdialysis experiments.
Microdialysis allows sampling of the extracellular fluid by
passive diffusion of substances over a semi-permeable
membrane. The recovery i.e. the amount of substances
that diffuse into the perfusion fluid depends on the tissue
and membrane properties, the flow rate, and the size of
the compound of interest [22]. Diffusion of low molecu-
lar substances over the dialysis membrane is almost com-
plete at low flow rates using a 30 mm long dialysis
membrane [23]. However, for larger molecules the recov-
ery over the membrane decreases and the measured levels
in the microdialysis sample may not be absolute concen-
trations in the tissue. The recovery of certain substance
may be measured in vitro, however, this in vitro recovery
can only be an estimate of the in vivo recovery since other
factors such as tissue pressure and temperature will affect
the diffusion of substances. For the in vivo recovery several
Table 1: Patient and tumor characteristics
123456789 1 0
A g e 6 75 95 18 68 36 65 66 86 55 7
Histology lobular ductal ductal ductal ductal ductal ductal lobular lobular ductal
S i z e  ( m m ) 1 8 9 2 06 02 02 01 71 55 02 1
D i s e a s e  s t a g e  ( T ) 1113221122
H i s t o l o g i c a l  g r a d e  ( N H G ) 2233222223
ER (%) 50 80 100 80 100 80 100 75 75 75
P R  ( % ) 1 0 0 1 008 0 1 0 0 0 0 05 00
Abbreviations: ER = estrogen receptor, PR = progesterone receptorBMC Cancer 2008, 8:73 http://www.biomedcentral.com/1471-2407/8/73
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calibration techniques such as the no net flux technique,
the stop flow techniques, and the endogenous reference
technique have been developed for low molecular sub-
stances unbound in the extracellular space. However,
when measuring high molecular weight proteins these
techniques may not be applicable because the proteins of
interest may be bound to binding proteins in vivo, recom-
binant proteins may not have the same properties as the
natural proteins in vivo, and plasma and tissue levels of the
protein are not equal. We have previously found that in
the case of VEGF tissue homogenate, unlike plasma VEGF,
correlate significantly with VEGF sampled by microdialy-
sis. We have previously reported an in vitro recovery of
VEGF of 8% and an in vitro recovery of estradiol from
plasma of 30% and these data were confirmed in the
present study [7,20]. In the present study all microdialysis
values are given as original raw data without any re-calcu-
lations.
Quantification of estradiol and VEGF
Measurements of estradiol in plasma and microdialysis
dialysate were conducted using a commercial quantitative
immunoassay kit (estradiol ELISA, DRG Instruments
GmbH, Marburg, Germany) according to the manufac-
turer's instructions. VEGF was quantified using a commer-
cial quantitative immunoassay kit for human VEGF
(Fluorokine MAP human VEGF kit, R&D systems, Abing-
don, UK) and analyzed by the Luminex 100 IS System
(Luminex B.V., Oosterhout, Netherlands). According to
the manufacturer, the VEGF kit measures the VEGF165 and
VEGF121 isoforms, and the mean minimum detectable
dose is 0.81 pg/mL. The intra-assay precision for this kit is
3.7–7% which was confirmed during the experiment. All
microdialysis values are stated as raw data.
Immunohistochemistry of tumor sections
Formalin-fixed, paraffin-embedded tumors were sec-
tioned, deparaffinized and subjected to anti-human VEGF
immunohistochemistry (monoclonal mouse anti-human
VEGF, specific for the VEGF165 and VEGF121 isoforms,
dilution 1:20, R&D systems, with Envision detection,
DAKO). Sections were counterstained with Mayer's hema-
toxylin. Negative controls did not show staining. In a
blinded manner, entire sections were first scanned to
determine the range of intensity of the staining. VEGF
staining was thereafter scored as weakly or strongly posi-
tive. Estrogen receptor (ER) and progesterone receptor
(PR) were determined by immunohistochemical staining
using the Ventana Benchmark system (Ventana Medical
Systems Inc., Arizona, USA) and defined as the fraction of
positive nuclei. Monoclonal rabbit anti-human estrogen
receptor alpha antibody (prediluted 1:50, Lab Vision Ltd,
Suffolk, UK) and monoclonal mouse anti-human proges-
terone receptor antibody (prediluted 1:50, Novocastra
Laboratories Ltd, Newcastle, UK) were used for staining.
Clinicopathological data
Tumor histology, size, stage (T of the TNM classification),
and Nottingham histological grade (NHG) according to
Elston Ellis scoring system were determined at the Depart-
ment of Pathology and Cytology, University Hospital of
Linköping.
Statistical analysis
Shapiro-Wilks' W test for normality was used. Wilcoxons'
signed rank test for paired observations was used and nor-
mally distributed data was calculated using Pearson's cor-
relation coefficient. Results are given in median [25–75
precentile].
Results
Characteristics of patients and tumors
Ten patients were included in the study, 7 with invasive
ductal carcinoma and 3 with invasive lobular carcinoma.
All of the tumors were ER-positive; 5 of 10 were PR-posi-
tive. Tumors were stage pT1-3 (TNM) and NHG 2–3. All
tumors showed positive scoring for mitosis (not shown).
Clinicopathological data is provided in Table 1.
Extracellular VEGF significantly higher in breast cancer 
tumors than in adjacent normal breast tissue
Using microdialysis, levels of estradiol and extracellular
VEGF were measured in tumors and in adjacent normal
breast tissue in vivo. Levels of intratumoral VEGF were sig-
nificantly higher than in normal breast tissue, 6.0 pg/mL
[4.1–6.5] in tumors compared to 2.4 pg/mL [2,3] in breast
tissue, p = 0.005, Wilcoxon signed rank test, Figure 1).
Plasma levels of VEGF were 3.67 pg/mL [0.8–5.7], range
0.62–7.59 pg/mL. In 7 of the 10 patients tumor estradiol
levels were higher than in normal breast tissue, however,
when comparing the whole group no significant differ-
ences were found between the levels of tumor estradiol,
106 pM [72–136], and normal breast tissue estradiol, 87
pM [48–150], Figure 2. Plasma levels of estradiol were 60
pM [40–84], range 24–198 pM.
Significant correlation between normal breast estradiol 
and breast VEGF in vivo
A significant positive correlation was found between
plasma levels and normal breast tissue levels of estradiol,
Figure 3. No correlations were found between tumor
estradiol and tumor VEGF or between plasma VEGF and
tumor VEGF. ER, PR, and tumor size did not correlate with
VEGF or estradiol measured in microdialysis dialysate or
plasma.
Immunohistochemistry of VEGF
All tumor sections showed positive intracellular staining
for VEGF. Inter-individual differences in intratumoral
VEGF quantified in microdialysis dialysate were not
reflected in the intensity of staining for VEGF.BMC Cancer 2008, 8:73 http://www.biomedcentral.com/1471-2407/8/73
Page 4 of 6
(page number not for citation purposes)
Discussion
To our knowledge this is the first report of intratumoral
sampling of extracellular estradiol and VEGF in vivo in
breast cancer patients. We show that tumor levels of extra-
cellular VEGF were significantly higher than those in adja-
cent normal breast tissue in vivo. In addition, we show a
positive correlation between normal breast tissue levels of
estradiol and extracellular VEGF in normal breast tissue in
vivo, in agreement with previous findings in a larger
cohort of healthy women [6].
Higher extracellular VEGF in tumor tissue compared to
normal tissue is in line with previous ex vivo findings dem-
onstrating an up-regulation of VEGF in breast cancer com-
pared to adjacent non-neoplastic tissue [24,25]. The inter-
individual differences in extracellular VEGF measured in
vivo were not apparent in the ex vivo immunohistochemi-
cal staining. This may be explained by the fact that the
shorter soluble isoforms of VEGF, which are sampled
using microdialysis, are not likely to be detected in the
extracellular space by immunostaining of tissue sections
[26]. The freely diffusible VEGF121  isoform has been
shown to be more angiogenic and tumorigenic than other
splice variants of VEGF and is considered the predomi-
Extracellular VEGF in normal breast and tumors of postmen- opausal breast cancer patients Figure 1
Extracellular VEGF in normal breast and tumors of 
postmenopausal breast cancer patients. VEGF sampled 
in vivo by microdialysis was significantly higher in tumors than 
in adjacent normal breast tissue (p = 0.005). Each symbol 
represents an individual patient.
Extracellular estradiol in normal breast and tumors of post- menopausal breast cancer patients Figure 2
Extracellular estradiol in normal breast and tumors 
of postmenopausal breast cancer patients. No signifi-
cant differences were found between the levels of estradiol 
in tumor and normal breast tissue sampled in vivo by microdi-
alysis. Each symbol represents an individual patient.BMC Cancer 2008, 8:73 http://www.biomedcentral.com/1471-2407/8/73
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nant isoform in human breast cancer [26,27]. Moreover,
our previous studies suggest that quantitative differences
in secreted VEGF are not necessarily detectable in semi-
quantitative immunohistochemical staining [6,8,9].
Hence, sampling VEGF in the extracellular space, where it
exerts its effects, may add significant insight into its regu-
lation in tumor tissue.
Previous ex vivo studies have shown that estradiol levels
may be higher in tumor tissue than in normal breast tissue
distant from the tumor [14,15]. The demonstration of
enzymes involved in estrogen synthesis in human breast
cancer has led to the intracrine concept that local estro-
gens produced in a breast tumor and surrounding tissue
contributes to tumor development and progression [16-
18]. In this study, estradiol levels measured in tumors in
vivo were indeed higher than in normal breast tissue in 7
of the 10 patients with up to three times higher levels of
estradiol in tumors, supporting possible intratumoral
estrogen production in some breast cancers.
While a significant correlation was found between normal
tissue estradiol and VEGF, there was no correlation
between levels of tumor estradiol and VEGF. Although all
tumors were ER positive, levels of expression varied
between patients and half of the tumors showed no PR
expression. Loss of PR expression has previously been
attributed to a non-functional ER [28], which may be one
reason for the absence of correlation between tumor estra-
diol and tumor VEGF. Therefore our results do not rule
out a possible regulation of VEGF by estradiol in breast
cancer tumors. Hypoxia is a potent regulator of VEGF and
tumor angiogenesis via hypoxia inducible factor-I [29,30],
and we have previously demonstrated a positive correla-
tion between tumor size and VEGF in experimental breast
cancer models [8,31]. Xenografts derived from cell lines
are however more homogeneous than human tumors due
to the use of only one clone of cancer cell [32]. In this
study both lobular and ductal carcinomas were included,
and tumor size varied between 9–60 mm. The heterogene-
ity and the small sample size may explain, at least in part,
the lack of correlation between tumor size and tumor
VEGF.
Plasma and tumor levels of VEGF did not correlate in this
study in line with our previous findings demonstrating
that less than half of the VEGF in circulating plasma orig-
inates from the tumor [7]. This suggests that determina-
tion of VEGF in plasma is a poor indicator of tumor VEGF.
The fact that estradiol may be synthesized and VEGF
mobilized locally in the breast and in breast cancer
emphasizes the need to sample these molecules in the
extracellular space. This study is the first of its kind to
measure VEGF and estradiol in human breast cancer
tumors in situ by microdialysis. Sampling regulators of the
tumor microenvironment directly in situ is highly desira-
ble taking into consideration that gene expression levels
and intracellular protein levels are not always indicative of
biologically active extracellular protein levels [8]. It may
be argued that the differences seen between tumor and
normal tissue merely reflect differences in recovery
between the tissues. However, tumor tissue have increased
blood flow compared to normal breast tissue which in
theory would decrease the recovery and result in
decreased levels of the compounds in the tumor. In our
present study tumor tissue exhibited higher levels of
VEGF. Hence, these results cannot be explained by possi-
ble differences of the in vivo recovery only. Moreover, cor-
relations are measured in the same sample from the same
tissue and these results are unaffected by different tissue
recoveries. While studies today are generally limited to in
vitro cell culture methods, animal models, and ex vivo sur-
gical specimens, microdialysis is emerging as unique tool
for in vivo sampling in accessible tumors such as those of
the breast [33].
Conclusion
Our findings show that the in vivo levels of extracellular
VEGF were significantly higher in breast cancer tumors
than in normal breast tissue. In addition, our results sup-
port the role of estradiol as a potent regulator of VEGF in
normal breast tissue in vivo. Further studies are warranted
to investigate the role of VEGF in mediating sex steroid
effects on breast cancer development and progression.
Correlation of local extracellular breast VEGF and estradiol  in normal breast tissue of breast cancer patients Figure 3
Correlation of local extracellular breast VEGF and 
estradiol in normal breast tissue of breast cancer 
patients. There was a significant correlation between extra-
cellular local breast estradiol (E2) and VEGF in normal breast 
tissue of breast cancer patients, (r = 0.708, p = 0.022).BMC Cancer 2008, 8:73 http://www.biomedcentral.com/1471-2407/8/73
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Novel in situ data provided by microdialysis may increase
our understanding of breast cancer tumor biology.
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